

Robert E Widdop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5513471/publications.pdf>

Version: 2024-02-01

114
papers

5,541
citations

57758

44
h-index

85541

71
g-index

133
all docs

133
docs citations

133
times ranked

5249
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical rodent models of cardiac fibrosis. <i>British Journal of Pharmacology</i> , 2022, 179, 882-899.	5.4	12
2	Optimising the photothrombotic model of stroke in the C57Bl/6 and FVB/N strains of mouse. <i>Scientific Reports</i> , 2022, 12, 7598.	3.3	7
3	N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT ₂ receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 29, 115859.	3.0	6
4	Combining mesenchymal stem cells with serelaxin provides enhanced renoprotection against 1K/DOCA/salt-induced hypertension. <i>British Journal of Pharmacology</i> , 2021, 178, 1164-1181.	5.4	12
5	Assessment of renal fibrosis and anti-fibrotic agents using a novel diagnostic and stain-free second-harmonic generation platform. <i>FASEB Journal</i> , 2021, 35, e21595.	0.5	8
6	In Aged Females, the Enhanced Pressor Response to Angiotensin II Is Attenuated By Estrogen Replacement via an Angiotensin Type 2 Receptor-Mediated Mechanism. <i>Hypertension</i> , 2021, 78, 128-137.	2.7	9
7	Using conformational constraints at position 6 of Angiotensin II to generate compounds with enhanced AT ₂ R selectivity and proteolytic stability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 43, 128086.	2.2	1
8	Relaxin Attenuates Organ Fibrosis via an Angiotensin Type 2 Receptor Mechanism in Aged Hypertensive Female Rats. <i>Kidney360</i> , 2021, 2, 1781-1792.	2.1	7
9	Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112256.	5.6	8
10	Esterase-Mediated Sustained Release of Peptide-Based Therapeutics from a Self-Assembled Injectable Hydrogel. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 58279-58290.	8.0	11
11	Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid. <i>Free Radical Biology and Medicine</i> , 2020, 160, 391-402.	2.9	16
12	Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity. <i>Chemistry - A European Journal</i> , 2020, 26, 10690-10694.	3.3	7
13	Serelaxin and the AT ₂ Receptor Agonist CGP42112 Evoked a Similar, Nonadditive, Cardiac Antifibrotic Effect in High Salt-Fed Mice That Were Refractory to Candesartan Cilexetil. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 76-87.	4.9	15
14	The anti-fibrotic actions of relaxin are mediated through AT ₂ -associated protein phosphatases via RXFP1-AT ₂ R functional crosstalk in human cardiac myofibroblasts. <i>FASEB Journal</i> , 2020, 34, 8217-8233.	0.5	18
15	Renal functional effects of the highly selective AT ₂ R agonist, $\hat{1}^2$ -Pro7 Ang III, in normotensive rats. <i>Clinical Science</i> , 2020, 134, 871-884.	4.3	15
16	A Series of Analogues to the AT ₂ R Prototype Antagonist C38 Allow Fine Tuning of the Previously Reported Antagonist Binding Mode. <i>ChemistryOpen</i> , 2019, 8, 114-125.	1.9	8
17	AT ₁ R-AT ₂ R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2191-2207.	6.1	35
18	A Novel Epigenetic Drug-Eluting Balloon Angioplasty Device: Evaluation in a Large Animal Model of Neointimal Hyperplasia. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 687-692.	2.6	3

#	ARTICLE	IF	CITATIONS
19	Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 64-73.	2.0	82
20	Morphology and Function of the Lamb Ileum following Preterm Birth. <i>Frontiers in Pediatrics</i> , 2018, 6, 8.	1.9	7
21	CCL18 as a potential mediator of the pro-fibrotic actions of M2 macrophages in the vessel wall during hypertension. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR1-4.	0.0	0
22	Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3750-3755.	7.1	180
23	The effect of tocopheryl phosphates (TPM) on the development of atherosclerosis in apolipoproteinâ€deficient mice. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 107-116.	1.9	12
24	Anti-fibrotic Potential of AT2 Receptor Agonists. <i>Frontiers in Pharmacology</i> , 2017, 8, 564.	3.5	58
25	Novel approaches for treating hypertension. <i>F1000Research</i> , 2017, 6, 80.	1.6	5
26	Decorated self-assembling Î² ³ -tripeptide foldamers form cell adhesive scaffolds. <i>Chemical Communications</i> , 2016, 52, 4549-4552.	4.1	29
27	Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. <i>Journal of Molecular Medicine</i> , 2016, 94, 957-966.	3.9	39
28	Compound 21, a selective agonist of angiotensin AT ₂ receptors, prevents endothelial inflammation and leukocyte adhesion <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Pharmacology</i> , 2016, 173, 729-740.	5.4	51
29	Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 56-68.	2.0	34
30	Î²-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats. <i>Clinical Science</i> , 2015, 129, 505-513.	4.3	34
31	Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2. <i>Frontiers in Pharmacology</i> , 2015, 6, 5.	3.5	17
32	PcTx1 affords neuroprotection in a conscious model of stroke in hypertensive rats via selective inhibition of ASIC1a. <i>Neuropharmacology</i> , 2015, 99, 650-657.	4.1	55
33	Effect of a Selective Mas Receptor Agonist in Cerebral Ischemia <i>In Vitro</i> and <i>In Vivo</i> . <i>PLoS ONE</i> , 2015, 10, e0142087.	2.5	26
34	Direct Angiotensin AT2 Receptor Stimulation Using a Novel AT2 Receptor Agonist, Compound 21, Evokes Neuroprotection in Conscious Hypertensive Rats. <i>PLoS ONE</i> , 2014, 9, e95762.	2.5	72
35	Differential Phenotypes of Tissue-Infiltrating T Cells during Angiotensin II-Induced Hypertension in Mice. <i>PLoS ONE</i> , 2014, 9, e114895.	2.5	40
36	Pressor responsiveness to angiotensin II in female mice is enhanced with age: role of the angiotensin type 2 receptor. <i>Biology of Sex Differences</i> , 2014, 5, 13.	4.1	30

#	ARTICLE	IF	CITATIONS
37	Angiotensin Type 2 Receptor Stimulation Increases Renal Function in Female, but Not Male, Spontaneously Hypertensive Rats. <i>Hypertension</i> , 2014, 64, 378-383.	2.7	49
38	Sex- and age-related differences in the chronic pressure-natriuresis relationship: role of the angiotensin type 2 receptor. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F901-F907.	2.7	55
39	Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. <i>Kidney International</i> , 2014, 86, 75-85.	5.2	98
40	Role of Inflammation and the Angiotensin Type 2 Receptor in the Regulation of Arterial Pressure During Pregnancy in Mice. <i>Hypertension</i> , 2014, 64, 626-631.	2.7	20
41	Electronic Sculpting of Ligand-GPCR Subtype Selectivity: The Case of Angiotensin II. <i>ACS Chemical Biology</i> , 2014, 9, 1420-1425.	3.4	31
42	Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease. <i>Hypertension</i> , 2014, 64, 315-322.	2.7	86
43	Update on the Angiotensin AT2 Receptor. <i>Current Hypertension Reports</i> , 2013, 15, 25-30.	3.5	51
44	Brain and retinal microglia in health and disease: An unrecognized target of the renin-angiotensin system. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 571-579.	1.9	32
45	Protective arms of the renin-angiotensin system in neurological disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 580-588.	1.9	75
46	Direct AT2 receptor stimulation is athero-protective and stabilizes plaque in Apolipoprotein E-deficient mice. <i>International Journal of Cardiology</i> , 2013, 169, 281-287.	1.7	25
47	The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE ^{-/-} mouse model. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 353-360.	2.0	121
48	Differential roles for tissue-infiltrating T cells during angiotensin II-induced hypertension. <i>FASEB Journal</i> , 2013, 27, 708.6.	0.5	0
49	Angiotensin II Type 2 Receptor Stimulation Initiated After Stroke Causes Neuroprotection in Conscious Rats. <i>Hypertension</i> , 2012, 60, 1531-1537.	2.7	54
50	Sex Differences in the Pressor and Tubuloglomerular Feedback Response to Angiotensin II. <i>Hypertension</i> , 2012, 59, 129-135.	2.7	84
51	Reversal of Vascular Macrophage Accumulation and Hypertension by a CCR2 Antagonist in Deoxycorticosterone/Salt-Treated Mice. <i>Hypertension</i> , 2012, 60, 1207-1212.	2.7	103
52	Ganging up on Angiotensin II Type 1 Receptors in Vascular Remodeling. <i>Hypertension</i> , 2012, 60, 17-19.	2.7	8
53	Sex-Specific Influence of Angiotensin Type 2 Receptor Stimulation on Renal Function. <i>Hypertension</i> , 2012, 59, 409-414.	2.7	95
54	Neuroprotective effect of an angiotensin receptor type 2 agonist following cerebral ischemia in vitro and in vivo. <i>Experimental & Translational Stroke Medicine</i> , 2012, 4, 16.	3.2	29

#	ARTICLE	IF	CITATIONS
55	Non-peptide AT ₂ -receptor agonists. <i>Current Opinion in Pharmacology</i> , 2011, 11, 187-192.	3.5	96
56	The effects of B-HT 920 and St 91 on venous haemodynamics in cats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 41, 55-56.	2.4	1
57	<i>Î</i> ² -amino acid substitution to investigate the recognition of angiotensin II (AngII) by angiotensin converting enzyme 2 (ACE2). <i>Journal of Molecular Recognition</i> , 2011, 24, 235-244.	2.1	5
58	Gender Differences in Pressure-Natriuresis and Renal Autoregulation. <i>Hypertension</i> , 2011, 57, 275-282.	2.7	112
59	A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE ^{-/-} mouse model. <i>Diabetes and Vascular Disease Research</i> , 2011, 8, 117-124.	2.0	152
60	A Single <i>Î</i> ² -Amino Acid Substitution to Angiotensin II Confers AT ₂ Receptor Selectivity and Vascular Function. <i>Hypertension</i> , 2011, 57, 570-576.	2.7	51
61	Chronic Administration of the HNO Donor Angeli's Salt Does Not Lead to Tolerance, Cross-Tolerance, or Endothelial Dysfunction: Comparison with GTN and DEA/NO. <i>Antioxidants and Redox Signaling</i> , 2011, 14, 1615-1624.	5.4	35
62	Relative affinity of angiotensin peptides and novel ligands at AT ₁ and AT ₂ receptors. <i>Clinical Science</i> , 2011, 121, 297-303.	4.3	241
63	Vasoprotective and Atheroprotective Effects of Angiotensin (1-7) in Apolipoprotein E ^{-/-} Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1606-1613.	2.4	145
64	Angiotensin AT ₂ Receptor Stimulation Causes Neuroprotection in a Conscious Rat Model of Stroke. <i>Stroke</i> , 2009, 40, 1482-1489.	2.0	101
65	Functional Cardiovascular Effects of Angiotensin Peptides: Focus on Atherosclerosis and Hypertension. <i>Current Hypertension Reviews</i> , 2009, 5, 227-236.	0.9	4
66	Response to Letter by Tsuda. <i>Stroke</i> , 2009, 40, .	2.0	1
67	VASCULAR ANGIOTENSIN AT ₂ RECEPTORS IN HYPERTENSION AND AGEING. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 386-390.	1.9	35
68	SEX ^â DIFFERENCES IN CIRCADIAN BLOOD PRESSURE VARIATIONS IN RESPONSE TO CHRONIC ANGIOTENSIN II INFUSION IN RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 391-395.	1.9	19
69	EARLY ORIGINS OF CARDIAC HYPERTROPHY: DOES CARDIOMYOCYTE ATTRITION PROGRAMME FOR PATHOLOGICAL ^â CATCH ^â UP ^â ™ GROWTH OF THE HEART?. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 1358-1364.	1.9	53
70	Nitroxyl (HNO): the Cinderella of the nitric oxide story. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 601-608.	8.7	243
71	Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma. <i>Atherosclerosis</i> , 2008, 200, 37-44.	0.8	24
72	Enhanced Angiotensin II Type 2 Receptor Mechanisms Mediate Decreases in Arterial Pressure Attributable to Chronic Low-Dose Angiotensin II in Female Rats. <i>Hypertension</i> , 2008, 52, 666-671.	2.7	143

#	ARTICLE	IF	CITATIONS
73	Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. <i>Cardiovascular Research</i> , 2008, 77, 178-187.	3.8	71
74	Response to Can the Study of Female Rats Help Our Understanding of Women?. <i>Hypertension</i> , 2008, 52, .	2.7	0
75	A Novel Histone Deacetylase Inhibitor Reduces Abdominal Aortic Aneurysm Formation in Angiotensin II-Infused Apolipoprotein E-Deficient Mice. <i>Journal of Vascular Research</i> , 2008, 45, 143-152.	1.4	51
76	Anti-atherosclerotic effects of the hexapeptide angiotensin IV. <i>FASEB Journal</i> , 2008, 22, 639-639.	0.5	0
77	Nitroxyl Anion Donor, Angeli's Salt, Does Not Develop Tolerance in Rat Isolated Aortae. <i>Hypertension</i> , 2007, 49, 885-892.	2.7	102
78	Immunolocalization of ACE2 and AT2 Receptors in Rabbit Atherosclerotic Plaques. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 147-150.	2.5	57
79	AT2 receptors mediate tonic renal medullary vasoconstriction in renovascular hypertension. <i>British Journal of Pharmacology</i> , 2005, 144, 486-492.	5.4	25
80	Differential cardiovascular responses to stressors in hypertensive and normotensive rats. <i>Experimental Physiology</i> , 2005, 90, 141-150.	2.0	53
81	Angiotensin-(1-7) Acts as a Vasodepressor Agent Via Angiotensin II Type 2 Receptors in Conscious Rats. <i>Hypertension</i> , 2005, 45, 960-966.	2.7	183
82	High Blood Pressure Reduction Reverses Angiotensin II Type 2 Receptor-Mediated Vasoconstriction Into Vasodilation in Spontaneously Hypertensive Rats. <i>Circulation</i> , 2005, 111, 1006-1011.	1.6	98
83	Differential gene expression in WKY and SHR brain following acute and chronic air-puff stress. <i>Molecular Brain Research</i> , 2005, 133, 329-336.	2.3	17
84	Central autonomic integration of psychological stressors: Focus on cardiovascular modulation. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2005, 123, 1-11.	2.8	45
85	Medial prefrontal cortical integration of psychological stress in rats. <i>European Journal of Neuroscience</i> , 2004, 20, 2430-2440.	2.6	60
86	Differential regulation by AT1 and AT2 receptors of angiotensin II-stimulated cyclic GMP production in rat uterine artery and aorta. <i>British Journal of Pharmacology</i> , 2004, 141, 1024-1031.	5.4	14
87	AT ₂ receptor-mediated vasodilatation is unmasked by AT ₁ receptor blockade in conscious SHR. <i>British Journal of Pharmacology</i> , 2004, 142, 821-830.	5.4	72
88	Vascular angiotensin II actions mediated by angiotensin II type 2 receptors. <i>Current Hypertension Reports</i> , 2004, 6, 117-123.	3.5	12
89	Angiotensin AT receptor contributes to cardiovascular remodelling of aged rats during chronic AT receptor blockade. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 1023-1030.	1.9	81
90	Localization of AT2 receptors in the nucleus of the solitary tract of spontaneously hypertensive and Wistar Kyoto rats using [125I] CGP42112: upregulation of a non-angiotensin II binding site following unilateral nodose ganglionectomy. <i>Brain Research</i> , 2003, 968, 139-155.	2.2	14

#	ARTICLE	IF	CITATIONS
91	Angiotensin AT ₂ receptors: cardiovascular hope or hype?. <i>British Journal of Pharmacology</i> , 2003, 140, 809-824.	5.4	201
92	Functional role of angiotensin II AT ₂ receptor in modulation of AT ₁ receptor-mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide. <i>British Journal of Pharmacology</i> , 2003, 140, 987-995.	5.4	80
93	High Methionine and Cholesterol Diet Abolishes Endothelial Relaxation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1358-1363.	2.4	48
94	Disparate Roles of AT ₂ Receptors in the Renal Cortical and Medullary Circulations of Anesthetized Rabbits. <i>Hypertension</i> , 2003, 42, 200-205.	2.7	42
95	AT ₂ Receptor-Mediated Relaxation Is Preserved After Long-Term AT ₁ Receptor Blockade. <i>Hypertension</i> , 2002, 40, 516-520.	2.7	146
96	Pharmacodynamic Contribution to the Vasodilator Effect of Chronic AT ₁ Receptor Blockade in SHR. <i>Hypertension</i> , 2001, 37, 91-98.	2.7	6
97	Characterisation of vasopressin V _{1A} , angiotensin AT ₁ and AT ₂ receptor distribution and density in normotensive and hypertensive rat brain stem and kidney: effects of restraint stress. Published on the World Wide Web on 2 October 2000.. <i>Brain Research</i> , 2000, 883, 148-156.	2.2	22
98	Restraint Stress. <i>Hypertension</i> , 2000, 35, 126-129.	2.7	113
99	Vasopressin V ₂ receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 276, R872-R879.	1.8	13
100	Cardiovascular Effects of Angiotensin-(1-7) in Conscious Spontaneously Hypertensive Rats. <i>Hypertension</i> , 1999, 34, 964-968.	2.7	52
101	AT ₂ Receptor Stimulation Enhances Antihypertensive Effect of AT ₁ Receptor Antagonist in Hypertensive Rats. <i>Hypertension</i> , 1999, 34, 1112-1116.	2.7	137
102	Type I and II metabotropic glutamate receptor agonists and antagonists evoke cardiovascular effects after intrathecal administration in conscious rats. <i>British Journal of Pharmacology</i> , 1999, 128, 823-829.	5.4	10
103	Modulation of AT ₁ receptor-mediated contraction of rat uterine artery by AT ₂ receptors. <i>British Journal of Pharmacology</i> , 1998, 125, 1429-1436.	5.4	43
104	A comparison of the development of renal hypertension in male and female rats. <i>Clinical Science</i> , 1998, 95, 445-451.	4.3	16
105	A Simple Versatile Method for Measuring Tail Cuff Systolic Blood Pressure in Conscious Rats. <i>Clinical Science</i> , 1997, 93, 191-194.	4.3	42
106	ROLE OF THE BRAIN RENIN-ANGIOTENSIN SYSTEM IN THE MAINTENANCE OF BLOOD PRESSURE IN CONSCIOUS SPONTANEOUSLY HYPERTENSIVE AND SINOARTIC BARORECEPTOR-DENERVATED RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1997, 24, 667-672.	1.9	6
107	Angiotensin Type I Receptor Antagonists CY-11974 and EXP 3174 Cause Selective Renal Vasodilatation in Conscious Spontaneously Hypertensive Rats. <i>Clinical Science</i> , 1996, 91, 147-154.	4.3	16
108	Electrophysiological studies of the cholecystininA receptor antagonists SR27897B and PD140548 in the rat isolated nodose ganglion. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1996, 353, 693-697.	3.0	7

#	ARTICLE	IF	CITATIONS
109	Regional Hemodynamic Effects of the AT 1 Receptor Antagonist CV-11974 in Conscious Renal Hypertensive Rats. <i>Hypertension</i> , 1995, 26, 989-997.	2.7	17
110	Electrophysiological and autoradiographical evidence for cholecystokinin A receptors on rat isolated nodose ganglia. <i>Journal of the Autonomic Nervous System</i> , 1994, 46, 65-73.	1.9	32
111	Effects of angiotensin II AT1- or AT2-receptor antagonists on drinking evoked by angiotensin II or water deprivation in rats. <i>Brain Research</i> , 1994, 648, 46-52.	2.2	19
112	Intrathecal kynurenate reduces arterial pressure, heart rate and baroreceptor-heart rate reflex in conscious rats. <i>Neuroscience Letters</i> , 1990, 114, 309-315.	2.1	26
113	Postjunctional α_2 -adrenoceptors mediate venoconstriction in the hindquarters circulation of anaesthetized cats. <i>British Journal of Pharmacology</i> , 1987, 92, 121-128.	5.4	10
114	Non-invasive tests of neurovascular function: Reduced responses in diabetes mellitus. <i>Neuroscience Letters</i> , 1987, 81, 177-182.	2.1	36